Pfizer (PFE) Share-based Compensation (2009 - 2026)

Pfizer has disclosed Share-based Compensation across 18 years of filings, most recently posting $272.0 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 60.0% year-over-year to $272.0 million; the TTM figure through Mar 2026 stood at $901.0 million (down 30.48% YoY), while the FY2025 annual figure was $799.0 million, down 8.89% from the prior year.
• Share-based Compensation improved to $272.0 million in Q1 2026, from $225.0 million in the prior quarter.
• Over the last five years, Share-based Compensation for PFE reached as high as $700.0 million in Q3 2024 and fell as low as $86.0 million in Q2 2022.
• The 5-year median for Share-based Compensation is $203.0 million (2025), against an average of $240.2 million.
• Annual changes were most pronounced in 2024 — Share-based Compensation soared 363.58% — and 2025, when it plunged 71.29%.
• A 5-year view of Share-based Compensation shows it stood at $508.0 million in 2022, then tumbled by 76.18% to $121.0 million in 2023, then surged by 478.51% to $700.0 million in 2024, then sank by 67.86% to $225.0 million in 2025, then rose by 20.89% to $272.0 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $272.0 million, $225.0 million, and $201.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.